Malcolm Reeves: Hey — before we do anything else, I need you to name six injectable peptides.
Cole Brennan: Oh no. BPC-157, TB-500... and then I start guessing.
Malcolm Reeves: KPV, MOTS-c, epitalon, semax. Those six — plus emideltide as the seventh — just went in front of the Pharmacy Compounding Advisory Committee, the PCAC, on July twenty-third and twenty-fourth. FDA staff scientists raised extensive concerns about every single one. No human clinical studies. And the outside advisory panel voted eight to six to recommend easing restrictions anyway.
Cole Brennan: Wait — eight to six after the FDA's own people said no? That's the structure inverted.
Malcolm Reeves: And now — the vote is non-binding. FDA still controls the 503A Bulks List, which is the actual gate here. But a committee going on record against the agency's own scientific staff, that has political weight even without legal force.
Cole Brennan: Huh. And emideltide got voted down — so the panel wasn't just uniformly pro-peptide. They drew a line somewhere.
Malcolm Reeves: Exactly — and that distinction matters for how we read the vote. This wasn't ideological rubber-stamping. The committee made specific judgments. Which makes the yes votes on the six harder to dismiss as politics and harder to defend as science.
Cole Brennan: So what we're actually trying to figure out — like the real question — is whether an eight-to-six non-binding vote from an outside panel can drag FDA policy somewhere the agency's own scientists don't want to go. That's the stakes here.
Malcolm Reeves: But here's what that non-binding vote is actually about — because the headline says 'FDA panel backs peptides' and that's not wrong, but it's not the real story. The real story is what the 503A Bulks List actually is.
Cole Brennan: Yeah — because I had to look this up and I think most people don't actually know what it is.
Malcolm Reeves: The 503A Bulks List is — at its core — a permission slip. A pharmacist can mix a custom drug for one specific patient using a listed ingredient. It was designed for the diabetic kid who needs an insulin concentration nobody manufactures commercially. That individual, that prescription, that dose.
Cole Brennan: Right — but the part that doesn't fit is... that's not remotely what's happening with BPC-157 and TB-500. Like, those two together — people call it the Wolverine stack — that's a mass consumer product. Joe Rogan talked about these on his platform, and then, I mean, telehealth clinics started shipping them to — I've seen figures suggesting it's a booming business, like genuinely commercial scale. That is not one pharmacist mixing one thing for one kid.
Malcolm Reeves: And that gap — between what 503A was designed for and what it became — that's the structural drift. A compounding pharmacy manufacturing peptides for a telehealth clinic that has ten thousand subscribers is running a distribution system for unapproved drugs. Through a pathway meant for individualized care.
Cole Brennan: Wait — and this was already happening before July 2026. The vote didn't create this market.
Malcolm Reeves: No. Adding BPC-157 or TB-500 to the 503A Bulks List would just legalize what was already running underground. The FDA had these on a restricted list as recently as 2025 — difficult to compound, effectively banned — and the market kept going anyway. The vote is about whether to formalize a system that built itself without permission.
Cole Brennan: So the actual new thing here — the thing the headline misses — is that this isn't the FDA deciding whether peptides are safe. It's the FDA deciding whether to retroactively sanction a commercial wellness market that the compounding pathway accidentally made possible. That's... actually a completely different question.
Malcolm Reeves: And that's where the RFK Jr. framing goes wrong — because the take circulating right now is 'he captured the FDA.' And I get why that's the shorthand. He called the 2023 restrictions illegal in February 2026. On the record. But that's a political assertion. Nobody adjudicated that. No court. No legal ruling. He just — said it.
Cole Brennan: Right — and he's not a neutral observer. He told people he's a, quote, 'big fan' of peptides and uses them personally.
Malcolm Reeves: Yes. So you have the HHS Secretary with a personal stake declaring the prior rules illegal — no court says so — and then, in April, twelve peptides get pulled from the Category 2 restricted list. That sounds like capture. But here's what actually happened in April.
Cole Brennan: Wait — that's the part I want people to hear. The twelve came off because the nominators withdrew their own nominations. No hearing. No new safety data. Just... gone.
Malcolm Reeves: No evidence presented. That's a procedural ghosting — not a scientific reassessment.
Cole Brennan: So — okay, wait, actually — that means the PCAC meeting in July, which was announced in April right after those twelve were pulled, is downstream of a procedural move, not a scientific one. The whole July hearing got scheduled on the back of a withdrawal, not new evidence.
Malcolm Reeves: Which is why I don't think the clean 'RFK captured this' story holds. He's real pressure — I'm not dismissing that. But the compounding system had already outgrown its guardrails. The gray market was running. FDA scientists were, I mean, they were raising alarms about unapproved drugs entering commercial wellness at scale through a pathway built for individual patients. That structural drift predates him.
Cole Brennan: No, I don't buy the clean causation either. He's accelerating something that already had velocity.
Malcolm Reeves: And if FDA follows the committee's vote on those six — BPC-157, TB-500, the rest — the precedent question is the one that keeps me up. Because that's where the real consequences land, and we haven't gotten there yet.
Cole Brennan: And that precedent question — like, let me try to make it concrete. Picture a 42-year-old, rotator cuff tear, Saturday afternoon, scrolling Instagram. Sponsored post from a telehealth clinic. He clicks, does a five-minute video call with somebody, and two days later — semax and BPC-157 arrive in a padded envelope from a compounding pharmacy in another state. That was already happening before July 2026. But if the FDA follows the PCAC vote and adds those to the 503A Bulks List — now it's legal. And trackable. Which actually changes what we know about who's using this stuff.
Malcolm Reeves: The trackability point is real. But the precedent cuts deeper than six compounds.
Malcolm Reeves: Look at what those six actually cover. BPC-157 and TB-500 for wound healing. KPV for inflammatory conditions. MOTS-c for metabolic and longevity. Epitalon for anti-aging. Semax for cognitive support. That's not a narrow carve-out — that's, I mean, that's basically a template across every major wellness category. And if a consumer demand wave plus a sympathetic administration is sufficient to route around clinical trials through the compounding pathway, then every other interest group with a popular compound is watching this vote very carefully.
Cole Brennan: Wait — so the real thing to watch isn't whether BPC-157 gets approved. It's whether adding something to the 503A Bulks List becomes the new strategy for bypassing standard approval entirely.
Malcolm Reeves: That's the structural consequence. Because the standard pathway requires clinical trials showing safety and efficacy. The compounding pathway — once you're on that list — skips that threshold. Those two things are not supposed to be interchangeable.
Cole Brennan: And the FDA — I mean, they haven't signaled which way they're going. The PCAC vote is non-binding, we said that. So the actual gate is still the FDA deciding whether to follow the recommendation. Which, given their own staff said no on all six...
Malcolm Reeves: That's the unresolved question. Popular and safe are not the same thing — and the PCAC vote did not resolve that tension. It just made it louder.
Cole Brennan: So the thing to watch is whether the FDA folds to the committee or holds its scientists' position. Because that decision — whatever it is — sets the template for every compound that comes after.
Malcolm Reeves: And the FDA hasn't moved yet. That's where it actually sits. The PCAC vote covers BPC-157, TB-500, KPV, MOTS-c, epitalon, semax — and the agency can still look at all six and say no. Their own scientists already said no. But now they're deciding in a political environment where the HHS Secretary has called the prior restrictions illegal and gone on record as a personal user. I don't know — I genuinely don't know what that pressure does to the final decision.
Cole Brennan: The part I keep sitting with — and I don't have an answer — is whether this is the proof of concept. Like, if the FDA does follow the committee, then someone else watched this whole sequence happen. The gray market builds, the influencer pipeline runs, a sympathetic administration declares the old rules illegal, twelve compounds disappear off a restricted list without a hearing, and then eight-to-six carries it over the line. That's a replicable playbook. And I — I don't know who runs it next.
Malcolm Reeves: History has a few of those moments. Remedies that got popular long before the evidence arrived. They don't all end badly. Some of them were fine. But we only know that in hindsight.
Cole Brennan: Yeah. That's not a reassuring note to end on, but it's the honest one. Good talk.
